Biotech company Immunai has closed a major investment from Koch Disruptive Technologies
Categories: Hi-Tech
Biotech company Immunai has closed a major investment from Koch Disruptive Technologies, which was lead investor alongside other new and existing investors.
Immunai works to map the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.
The investment of appx. USD 215 million will allow the company to continue breaking new grounds in this innovative and important field.
The Herzog team comprised partners Yair Geva and Yuval Zilber, with their team and associate Reggev Mechalovich.